DOT™ Myopia Control Spectacle Lenses Available for Early Access in the U.K.

Unique design leverages contrast management to slow childhood myopia progression

 

SOUTHAMPTON, September 22, 2025—DOT™ myopia control spectacle lenses by SightGlass Vision are now available for early access in the U.K. Designed to utilize contrast management, these lenses provide an effective way for clinicians and families to help fight the growing epidemic of childhood myopia.

In the U.K., the prevalence of myopia in children has more than doubled over the past 50 years, with onset starting at a younger age, increasing their likelihood of higher myopia later in life.^1,2 Every diopter of myopia progression increases the risk of serious eye conditions, but every diopter saved can reduce future eye health risk by up to 40%.³  

“Introducing DOT™ lenses in a new country is always an exciting moment for us because it means we can offer even more eye care professionals this globally trusted tool to protect their young patients’ vision,” said Andrew Sedgwick, CEO of SightGlass Vision. “With over one million children already having worn DOT™ lenses,^* we look forward to working with the U.K. optical community to expand access, intervene early, and help preserve children’s eye health with this highly effective technology.”

Clinical studies have demonstrated DOT™ lenses’ efficacy and comfort: they can slow average myopia progression by up to 75% after 12 months of wear across diverse populations, and 93% of children said they love their glasses with DOT™ lenses.^4,5,6,7,‡ 

SightGlass Vision will be hosting a webinar on 15 October, “Manage Contrast to Manage Myopia: Introducing DOT™ Lenses,” where U.K. eye care professionals can learn more about the unique lens design, the supporting clinical research, and ask questions to senior members of the SightGlass Vision team during a live Q&A. Registration for the webinar is now open here.

U.K. eye care professionals interested in being among the first to fit DOT™ lenses in their practices are invited to contact SightGlass Vision Greg Cahill, Sales Project Manager U.K. & Ireland, at [email protected].

Founded in 2016, SightGlass Vision is a joint venture of CooperCompanies and EssilorLuxottica.
For more information, visit SightGlassVision.com.

 

About SightGlass Vision

SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™ is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of light-scattering elements designed to mimic more natural contrast on the retina — a method intended to reduce myopia progression in children. The treatment has completed the three years pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.

^*This figure is based on sales data and reflects global usage across multiple regions.
^†SightGlass Vision™ Diffusion Optics Technology™ spectacle lenses are not available for sale in the United States.
^‡Patient population aged 6–10 years (CYPRESS) and 6–13 years (CATHAY). Lenses were worn 10 hours per day.

 

Media Contact
Carson Daniels, Senior Counselor
McDougall Communications for SightGlass Vision
+1-315-427-6394 or [email protected]